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life expectancies in the world, has invested heavily in domestic R&D and gener-
ics manufacturing in response to the U.S. embargo, and has been successful with 
achieving marketing authorization in multiple countries for its biopharmaceutical 
products. In Iran, international sanctions have led the government to encourage 
domestic production, which supplies 70-90% of the market. A possible relaxing of 
sanctions pending a deal on Iran’s nuclear program may pave the way for a multi-
national presence and increasing access to life-saving medicines. ConClusions: 
In general, the lifting of economic sanctions is observed to have positive impact on 
innovative pharmaceuticals, from both market access and technology transfer per-
spectives. The imposition of sanctions, however, may open the opportunity for local 
manufacturing and industrial innovation. Regardless of commercial and broader 
economic consequences, the lack of access to innovative pharmaceuticals may 
compromise optimal health care delivery in those affected countries.
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objeCtives: The objective of this study was to assess implications of the recent 
update to Russia’s Essential Drugs List (EDL) and Seven Nosologies (VZN) on the 
access of the local pharmaceutical market in the context of various economic pres-
sures. Methods: This study was based on the review of current and past iterations 
of the EDL and VZN, various policy changes, as well as economic and health outcome 
indicators. In addition, a pragmatic literature review was undertaken to assess the 
impact of the EDL and VZN updates on the current market access environment in 
Russia. Results: The 2015 EDL, which was previously updated in 2012, includes an 
additional 50 therapies, some of which are reimbursed through the VZN. Five new 
molecules were included within the VZN, including treatments for hemophilia, a 
cure for Gaucher’s disease, and a second-line therapy for multiple myeloma, bring-
ing the total to 23 therapies since its implementation in 2008. The 2013 decision to 
delegate the financial responsibilities (tenders) and implementation of the VZN to 
regional authorities by January 2015 to alleviate federal burden, did not materialize 
as expected, mainly due to cost concerns. 67% of 608 EDL therapies are manufac-
tured domestically, which is a reflection of their evolving pharmaceutical access 
policy due to economic pressure; in addition, only 35% of the 20,000 INNs marketed 
in Russia are reimbursed at the federal or state level while the rest are paid out-
of-pocket. ConClusions: The expansion of the EDL and VZN have made some 
innovative therapies available to certain populations that were previously unable to 
access these high-cost treatments. In addition, due to economic uncertainties, laws 
have been enacted to restrict the admission of foreign drugs to state procurement 
if equivalent INNs are available through local manufacturers.
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bACkgRound: Immunization decision-making (IDM) is usually based on multiple 
sources of evidence. Health economics (HE) has become increasingly relevant in IDM 
as one aspect to be considered. Objective of this study was to generate a consensus 
among stakeholders on how to implement HE into IDM in Germany. Method: We 
conducted a systematic literature review in order to identify relevant methods and 
advantages of considering HE evidence in IDM. Furthermore, an overview of IDM 
in several European countries was compiled based on literature. The generated 
evidence was used to prepare a national stakeholder symposium in January 2015 
on which representatives from academia, politics, industry, administration and 
patient-support groups were able to discuss different options on how to implement 
HE into IDM. Results: Based on the literature review five core advantages from 
considering HE aspects in IDM were identified: (I) modelling of future vaccine related 
public health effects; (II) identification of the most efficient vaccination strategy; 
(III) identification of critical input parameter; (IV) budget-impact-analysis; and (V) 
decision-making based on an incremental cost-effectiveness threshold. A recently 
conducted survey showed that most European countries consider HE in IDM. This 
is done (a) most frequently via an informal appraisal, (b) rarely by using a cost-
effectiveness threshold (4 countries), and (c) never by applying multiple-criteria 
decision-analyses. After key-note lectures, group-works and panel discussions, the 
majority of stakeholders had the opinion that in Germany the core advantages of (I) 
to (III) should be taken into account and decisions should be derived from an infor-
mal appraisal. disCussion: Most of the invited stakeholders acknowledged the use 
of HE in IDM. There was consensus that in Germany a cost-effectiveness threshold 
is no option. However, HE might be considered in IDM to compare different vac-
cination strategies and highlight the potential (economic) benefits of vaccination.
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objeCtives: The institutionalization of health technology assessment (HTA) 
remains a major challenge for many countries. Normative, political and social vari-
ations across nations limit the transference of HTA institutionalization models 
that have been implemented elsewhere. The “Knowledge to action” (KA) model 
has proven to reduce the “evidence-practice” gap through a systematic method 
of linking evidence to implementation and monitoring processes. The objective of 
data infrastructure, and some companies are advanced than others in tackling this 
issue. ConClusions: All respondents believed that MEAs will be used more fre-
quently. Performance-based schemes, while more difficult to be put in practice, are 
expected to become critical in disease areas like oncology.
HealtH caRe Use & Policy stUdies – conceptual Papers
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bACkgRound: The increasing focus on healthcare costs, aging of populations and 
rising costs of drug development require an effective approach to ensure the rational 
uptake and diffusion of technologies by health systems. Health stakeholders want 
safe, appropriate and effective healthcare with enduring results at a reasonable cost, 
particularly in environments where resources are scarce. In spite of much research, 
methodologies and recommendations, a simple solution to make budget allocations 
or procurement decisions is still needed by many decision makers. AppRoACh: A 
user-friendly and read-do checklist could facilitate the assessment of cost-effec-
tiveness of technologies, particularly new, innovative high cost drugs. The aero-
nautical industry (pre-flight safety checklist), World Health Organization/Harvard 
School of Public Health (pre-surgical safety checklist) and public health services 
(pre-disaster or disease preparedness checklists) have successfully prevented 
and reduced air traffic accidents and morbidity and mortality secondary to sur-
gical interventions, diseases and natural disasters through the implementation 
of safety checklists. pRACtiCAl iMpliCAtions: In pharmacoeconomics, as in 
aviation, medicine and public health, a checklist can help ensure consistency and 
completeness in carrying out the complex technology selection task improving 
the decision maker´s communication and consistency of information and data, 
facilitating the decision-making process and determining the most cost-effective 
options. This checklist could also be a useful tool to negotiate value added services, 
managed-entry agreements and risk-sharing arrangements to reduce the cost of 
drugs. ConClusions: A generic “New Technology Cost-Effectiveness Checklist”, 
intended to be modified as needed to fit local requirements, could guide evidence-
based decisions in resource-limited settings. In turn, it may become the tool to 
reach the universal goals of patients, providers, payers and policy-makers to (1) get 
the best drug and technology quality at the lowest cost and with reasonable access, 
and (2) enhance healthcare partnerships and solutions towards improved individual 
and population health outcomes.
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objeCtives: Recently the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) 
have been introduced. The scale is supposed to assist decisions about value and 
cost-effectiveness of new cancer therapies. This is done by classifying therapeutic 
advances according to their relative clinical benefit according to pre-defined cri-
teria. The objective of the present study was to investigate the scale from a health 
economics perspective. Methods: We conducted a critical appraisal of the build-
ing blocks of the scale in order to assess potential limitations to using the instru-
ment to inform policy. Results: Several issues that makes the scale problematic 
were identified. Three key areas of concern were: ESMO-MCBS uses different scales 
depending on if the intent of the therapy of to be curative or not. It is impossible to 
compare two cancer treatments which both have effect on survival and quality of 
life if the intension of the two therapies are different, yet they would compete for the 
same resources within the health care system. The ranking used is created based on 
expert opinion. It is unclear how these rankings would relate to the preferences of 
the patients or the general public. The scale relies on clinical trials as the evidence 
base. What matters for reimbursement agencies, payers and health care providers 
is how well the new treatment opportunity performs in clinical practice, in relation 
to existing therapeutic alternatives. ConClusions: There are limitations to the 
ESMO-MCBS at present as a measure of value. One important aspect that would 
merit further study is to validate how well the scale is able to discriminate between 
more and less valuable therapies as perceived by reimbursement bodies, by for 
instance comparing the rankings of therapies according to ESMO-MCBS to rankings 
based on estimated gains in survival and quality-adjusted survival.
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objeCtives: The objective of this study was to analyze the impact of imposed 
and/or withdrawn economic sanctions on various countries on access to innova-
tive pharmaceuticals, market access, and health outcomes. Recent geopolitical and 
pharmaceutical market dynamics related to Russia, Cuba, and Iran. Methods: This 
study examined the current health care financing options and market access impli-
cations of pharmaceuticals in Russia, Cuba, and Iran in light of the introduction or 
removal of sanctions on these markets. Intellectual property regulations, healthcare 
financing and procurement options, and domestic R&D investment were the key 
metrics evaluated in this research. Results: Due to sanctions imposed, Russia has 
pivoted from nearly solely an importation pharmaceutical market, to developing 
relevant policy framework to provide preferential access to locally-manufactured 
products (both from foreign and local manufacturers). Cuba, with one of the highest 
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objeCtives: The current trend in HTA is its application to local medical facilities 
(called hospital-based HTA or HB-HTA), where HTA methods can foster strategic 
decisions of the hospital management, especially in employing and/or procurement 
of new technology. The essence of HB-HTA utilization is to implement processes that 
allow assessment of the technology considering specific conditions of the hospital. 
Although there are multiple concepts of HTA implementation that can be tailored 
to the particular hospital´s needs, establishing a HTA unit seems the most practical 
in the case of big university hospitals. Methods: The models must be tailored for 
the Czech healthcare system and specific conditions of the particular hospital. The 
processes accommodated for evaluating, making decisions about and incorporat-
ing technologies are described to supportthe Motol University Hospital’sBoard of 
Directors. The hospital comprises all medical specialties and shows rich technologi-
cal equipment including necessary expertize, providing sufficient internal resources 
for HTA analyses focused on clinical practice. Results: Based on a management 
needs survey, assessment requirements are divided into four categories according 
to their urgency: 1. Urgent, immediate risk of service (device operation) interruption. 
2. Technology requires to be substituted due to impracticability of its recovery. 3. 
Technology requires to be expanded due to existing demand. 4. Incorporation of 
new innovative technology or planned replacement of obsolete technology. For each 
category, a flow chart was designed specifying the assessment process and assess-
ment team composition. The processes have been tested in introducing advanced 
point of care testing methods into the clinical practice in the Motol University 
Hospital. CONCLUSION: The model will be used for establishing working procedures 
of the intended HTA Unit in the Motol University Hospital, and further tested and 
enhanced in line with practical experience. The process is supported by the hospital 
management, who have collaborated on model adjusting.
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bACkgRound: Ireland is one of few countries worldwide to have an explicit cost-
effectiveness threshold. It was agreed in a 2012 agreement between government and 
the pharmaceutical industry. In conjunction with substantial cost-savings on exist-
ing medications the agreement established a threshold of € 45,000/QALY. Prior to this 
there had been an unofficial threshold of € 20,000/QALY. The agreement only applies to 
pharmaceuticals, so there remains no official threshold for non-drug interventions. 
According to the agreement, drugs with cost-effectiveness ratios within the thresh-
old will be granted reimbursement, whereas those exceeding the threshold may 
still be approved following further negotiation. A number of drugs far exceeding 
the threshold have been approved recently. AnAlysis: There are four reasons for 
concern regarding Ireland’s threshold. Firstly, that it only applies to drugs creates 
potential inconsistencies and inefficiencies whereby relatively cost-effective non-
drug interventions are not approved while expensive drugs are. Secondly, as a price 
floor rather than ceiling it offers only a weak constraint on the introduction of cost-
ineffective interventions. Thirdly, it has no apparent empirical basis. Finally, a recent 
threshold estimate based on the cost-effectiveness of services forgone for the UK 
was approximately £13,000/QALY. Assuming Ireland’s threshold should be broadly 
comparable, the current threshold is probably too high. ConClusion: An excessive 
threshold risks causing the Irish health system unintended harm, as newly adopted 
interventions may produce less health than alternative interventions foregone. 
The lack of an empirically-informed threshold means the policy recommendations 
of cost-effectiveness analysis cannot be considered fully evidence-based rational 
rationing. Finally, it also means that the current threshold does not accord with 
recent legislation on the pricing of medical goods, which defines cost-effectiveness 
in terms of the opportunity cost of other services foregone. Policy makers should 
consider these issues when choosing what threshold to apply once the current 
industry agreement expires at the end of 2015.
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objeCtives: Hernia repair is one of the most commonly performed surgical 
procedures. Hernia societies encourage surgical decisions based on up-to-date 
evidence-based guidelines rather than surgical intuition. The objective was to 
identify whether surgical guidelines and protocols for hernia repair can reduce 
costs and improve patient outcomes, and whether they are followed. Methods: 
Comprehensive literature search to identify publications on hernia repair guide-
lines and summarise their impact on cost and patient outcomes. Results: A 
Dutch study that compared inguinal hernia repair outcomes before and after evi-
dence-based guidelines were introduced showed a significant reduction in hernia 
recurrence when guidelines were followed. A Spanish study of emergency ventral 
hernia repairs found that the proportion of patients treated after introduction of 
a protocol was significantly lower for mortality following bowel resection and the 
incidence of severe complications was reduced (excluding femoral hernia) versus 
pre-protocol. Introduction of a protocol for inguinal hernia repair in a UK general 
hospital improved patient outcomes to a level comparable with a specialist hernia 
centre. The authors also reported potentially large cost savings by increasing the 
proportion of ambulatory patients and those that received local anaesthesia. The 
Royal College of Surgeons noted that ambulatory operations are recommended 
for 80% of groin hernia repairs but found that only 67% were ambulatory, rang-
ing from 32–100% across UK healthcare providers. Another UK study looked at the 
uptake of NICE guidelines for several procedures, including laparoscopic repair of 
inguinal hernia, and reported that although Hospital Episode Statistics suggested 
96% compliance, a detailed audit of healthcare trusts showed only 65% compli-
this study was to analyze how the KA model could be institutionalized within the 
HTA framework. Methods: We conducted a systematic search on “KA” theoretical 
approaches and empirical evidence. Based on a comparative analysis of relevant 
articles, and over a series of discussion meetings with different stakeholders, we 
generated an adjusted KA model fitting the purposes of HTA. Then, we identified the 
key institutional questions that would be relevant for the institutionalization of the 
adjusted KA model in the context of HTA. Results: The evidence on the KA model 
focuses on solving real problems, the use of evidence from different sources, and the 
need of including preferences of evidence users in real life, all elements included in 
the adjusted version. The institutionalization of KA within the HTA framework is 
challenged by, at least, the following questions: (i) which is the right way of choosing 
representative evidence users (e.g. healthcare team), stakeholders (health policy 
makers), and those affected by evidence use (patients); (ii) how to monitor the adap-
tation of guidelines to local contexts, (iii) which are the sets of rules that model the 
stakeholder´s behaviour, (iv) and which are the implied outcomes that are expected 
from these rules. ConClusions: The KA model adds important elements to HTA, 
which can be useful for the institutionalization processes in many countries of the 
world. This piece of research identified the main components/questions that need 
to be addressed to undertake this institutional process.
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bACkgRound: Mature products (MPs - marketed for 10 years or more) are widely 
used off label (from 15 to 35% according to studies) despite little evidence on benefit 
risk ratio. This exposes patients to risks or lack of efficacy and healthcare providers 
to liability. However manufacturers are rarely investing in R&D development for MPs. 
Indeed MPs face price cuts in Europe, whether due to generic competition, price 
negotiations or inclusion in reference price groups. Moreover new indications, even 
if demonstrating a higher value of the drug, often lead to price reductions in Europe 
due to a combination of price/volume agreements and external reference pricing. 
Products are included in reference price groups even for a new indication. While refer-
ence price groups only include off-patent drugs in France and Italy, these groups may 
include patented drugs in Spain (if older than 10 years) and Germany.There are sig-
nificant disincentives for manufacturers to invest in R&D for MPs, preferring instead 
to develop new molecular entities rather than unlocking the full therapeutic potential 
of MPs. This is especially the case for small populations (rare and ultra-rare diseases) 
where there is high unmet medical need and MPs could offer cost-effective solutions 
with known safety profiles. disCussion: The development of new indications for 
MPs can be a win-win solution for patients and payers. It offers an alternative to off 
label or lengthy and expensive development of new therapies, as well as more equity 
in patients’ access to treatment. As safety accounts for approximately 30% of drug 
failures in clinical trials, mature products can also offer a quicker and less expensive 
access to therapy, especially in areas of high unmet need. ConClusion: Incentives 
for orphan drugs or pediatric indications have proven to be effective in promoting 
R&D. New incentives should be developed to promote R&D in MPs.
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Developing countries moving to universal coverage seek to increase medicine 
access. They face the problem of determining which medicines to reimburse and 
how to set price and access for them. Medicine price and access are set by many 
organisations in developing countries - ministry of health, hospitals, national/
regional payers and procurement bodies - with limited or no data on prices and 
utilisation. This leads to a fragmented system with widely varying price and access 
levels within the same country. Ad hoc solutions such as median pricing, inter-
national price referencing (IRP), HTA or arbitrary price cuts, with no overarching 
framework or logic, exacerbate the problems leading to supply shortages, poor 
quality, irrational use and continuing large differences in price and access. There is 
no consistent mechanism for setting price and access for innovative medicines. In 
the few countries performing cost-effectiveness assessments, these medicines are 
almost never found to be cost effective at local thresholds. In this paper, we lay out 
a structured Pricing and Patient Access (PPA) framework that empowers countries 
with effective approaches and tools to price medicines. These include competi-
tive pricing for generics and setting price/access based on benefit assessment 
for patented medicines. Specific tools such as IRP, therapeutic referencing and 
price-volume/risk-share negotiations and managed entry agreements can then be 
used within this overall framework to improve access to priority medicines. While 
many of these tools exist in developed countries, we develop specific adaptations 
for developing countries. Further, building of such systems faces obstacles such 
as a cognitive disconnect between what stakeholders think they know and what 
they really know about PPA, institutional fragmentation, stakeholder buy-in and 
limited local capabilities (number of staff, skills, IT systems to track price and 
utilisation). To address these we also lay out a pathway to reform that addresses 
each of these issues.
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